Profit compounding faster than revenue
Over 4 years profit compounded at 19.6% a year while revenue compounded at 10.1% a year.
Importance 62 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Over 4 years profit compounded at 19.6% a year while revenue compounded at 10.1% a year.
Importance 62 / 95 · growth
Profit grew 17.9% while revenue grew 11.1%, so the company kept more of each rupee of revenue as profit.
Importance 60 / 95 · growth
Net worth compounded at 13.7% a year over 4 years (₹6,603 → ₹11,049).
Importance 54 / 95 · financial health
Classified by the exchange under Commodities › Chemicals › Chemicals & Petrochemicals › Specialty Chemicals.
Peer set used on this page: 3 chemicals & petrochemicals.
Over 4 years profit compounded at 19.6% a year while revenue compounded at 10.1% a year.
Rule PROFIT_CAGR_VS_REVENUE_CAGR
Profit grew 17.9% while revenue grew 11.1%, so the company kept more of each rupee of revenue as profit.
Net profit grew 17.9% year on year (FY2025 → FY2026).
Revenue has compounded at 10.1% a year over 4 years (₹9,921 → ₹14,601) — steady rather than rapid.
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q1 FY27 net profit was ₹884 cr, up 30.3% from ₹678 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q1 FY27 revenue was ₹4,552 cr, up 21.3% from ₹3,753 cr in Q1 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q1 FY27 EBIT was ₹1,189 cr, up 27.8% from ₹930 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q2 FY25 | 3,235 | — | 540 | — | 16.7% |
| Q3 FY25 | 3,369 | +7.6% | 557 | +9.0% | 16.5% |
| Q4 FY25 | 3,141 | +8.2% | 428 | +40.5% | 13.6% |
| Q1 FY26 | 3,753 | +10.5% | 678 | +18.7% | 18.1% |
| Q2 FY26 | 3,554 | +9.9% | 585 | +8.2% | 16.4% |
| Q3 FY26 | 3,710 | +10.1% | 624 | +12.0% | 16.8% |
| Q4 FY26 | 3,583 | +14.1% | 584 | +36.6% | 16.3% |
| Q1 FY27 | 4,552 | +21.3% | 884 | +30.3% | 19.4% |
Trailing twelve months to 30 Jun 2026 · sum of the last 4 contiguous quarters
EBITDA margin of 25.9% is the widest in 4 years (prior range 17.2% to 24.8%).
Rule MARGIN_AT_MULTI_YEAR_HIGH
Net worth compounded at 13.7% a year over 4 years (₹6,603 → ₹11,049).
Rule NET_WORTH_COMPOUNDING
Operating cash flow has matched or exceeded reported profit in 4 of the last 5 profit-making years (latest 1.15×).
Free cash flow has been positive in 5 of the last 5 years.
Ranked against 3 chemicals & petrochemicals (FY2026, consolidated). No peer-relative rule fired for this company.
PIDILITIND · 2nd of 3 · set median 11.1%
PIDILITIND · 2nd of 3 · set median 25.9%
PIDILITIND · 2nd of 3 · set median 23.5%
PIDILITIND · 2nd of 3 · set median 55.9×
On the trailing twelve months. Last full year: P/E 60.6× · P/S 10.1× · ROE 23.5%.
Over 4 years profit compounded at 19.6% a year while the stock returned 6.4% a year — the FY2022 base was somewhat depressed, so part of this is recovery rather than trend.
Rule STOCK_LAGGED_EARNINGS · rebound
Price-action indicators as of 2026-10-01. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
Nothing is flagged for review for this company.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 8,340 | 10,597 | 11,167 | 12,073 | 13,488 |
| Total income | 8,571 | 10,660 | 11,333 | 12,367 | 13,766 |
| EBITDA | 1,829 | 1,918 | 2,715 | 3,129 | 3,579 |
| Profit before tax | 1,627 | 1,668 | 2,404 | 2,766 | 3,194 |
| Net profit | 1,269 | 1,257 | 1,799 | 2,074 | 2,384 |
| EPS (₹) | 25.0 | 24.7 | 35.4 | 40.8 | 23.4 |
| Net worth | 6,417 | 7,108 | 8,337 | 9,676 | 10,665 |
| Total debt | 105 | 0 | 0 | 0 | 0 |
| Operating cash flow | 766 | 1,432 | 2,586 | 2,228 | 2,643 |
| Free cash flow | 451 | 1,004 | 2,082 | 1,799 | 2,072 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 27.1 | 5.4 | 8.1 | 11.7 |
| Profit growth YoY | — | -0.9 | 43.1 | 15.2 | 15.0 |
| Profitability | |||||
| EBITDA margin % | 21.9 | 18.1 | 24.3 | 25.9 | 26.5 |
| Net margin % | 14.8 | 11.8 | 15.9 | 16.8 | 17.3 |
| Return on equity % | 19.8 | 18.6 | 23.3 | 23.0 | 23.4 |
| Return on capital % | 25.4 | 24.9 | 31.4 | 31.3 | 31.9 |
| Leverage & cash | |||||
| Debt to equity | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash flow ÷ profit | 0.60 | 1.14 | 1.44 | 1.07 | 1.11 |
| Current ratio | 1.67 | 1.86 | 2.08 | 2.29 | 2.35 |